This session highlights the latest innovations in structural and valvular cardiology, featuring novel technologies such as a new self-expandable transcatheter aortic valve for aortic stenosis treatment and a temporary atrioventricular sequential pacing system. It also discusses non-clinical testing methodologies supporting U.S. market approvals, non-invasive ultrasound therapy...

Discover cutting-edge innovations in vascular therapies highlighting novel technologies such as Pulse Intravascular Lithotripsy (IVL) for calcium modification and Amplitude Vascular Systems. The session also presents drug-free restenosis control strategies via CD31 camouflage coating promoting physiological-grade healing, emphasizing emerging solutions aimed at improving vascular intervention outcomes.

This session provides a comprehensive guide to large-bore venous access and vessel closure techniques, emphasizing best practices and the advantages of ultrasound-guided suture mediated vessel closure compared to traditional figure-of-eight suture methods. It also addresses strategies to avoid and manage potential complications encountered during these procedures.

Examine diverse clinical scenarios and management strategies for aortic paravalvular leaks (PVL), including complex percutaneous closures post-TAVI and surgical interventions. This session presents challenging cases demonstrating varied presentations and approaches such as mechanical valve loop utilization, highlighting the complexities and tailored solutions required for successful PVL...

Martin Bergmann reviews the evolving evidence for LAAC, examining how recent landmark trials such as OPTION, CLOSURE‑AF and CHAMPION‑AF are reshaping patient selection and expanding the role of LAAC across a broader spectrum of patients with atrial fibrillation.

Fernando Alfonso and Javier Cuesta discuss the growing role of drug-coated balloons as an alternative to stents in percutaneous coronary interventions. Highlighting advantages like reduced in-stent restenosis, they emphasize the need for robust clinical studies to refine DCB use.

In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.